-transparent.png){kind=logo}
Treatment resistant recurrent herpes simplex persisting for years in 7 patients was treated with thymopoietin pentapeptide for 6 weeks, 50 mg subcutaneously three times per week. During treatment and follow-up of 6 weeks a pronounced reduction of frequency and duration of recurrences were observed. There was some tendency for normalisation of deranged lymphocyte and granulocyte function. The mode of action of thymopoietin pentapeptide in recurrent herpes simplex remains uncertain. An indirect effect via stimulation of production of interferon may be assumed.
Related Publications
D Djawari, and
K Bolla, and
E Haneke
November 1983,
Journal of the American Academy of Dermatology,
D Djawari, and
K Bolla, and
E Haneke
March 1983,
Lancet (London, England),
D Djawari, and
K Bolla, and
E Haneke
September 1964,
British medical journal,
D Djawari, and
K Bolla, and
E Haneke
May 1956,
Wiener klinische Wochenschrift,
D Djawari, and
K Bolla, and
E Haneke
July 1978,
Archives of dermatology,
D Djawari, and
K Bolla, and
E Haneke
May 1979,
Antimicrobial agents and chemotherapy,
D Djawari, and
K Bolla, and
E Haneke
December 1980,
Cutis,
D Djawari, and
K Bolla, and
E Haneke
May 1981,
Minerva medica,
D Djawari, and
K Bolla, and
E Haneke
July 1957,
Zeitschrift fur Haut- und Geschlechtskrankheiten,
D Djawari, and
K Bolla, and
E Haneke
January 1991,
Giornale italiano di chemioterapia,
